Literature DB >> 25005594

Sociodemographic disparities in administration of antiepileptic drugs to adults with epilepsy in Germany: a retrospective, database study of drug prescriptions.

Hajo M Hamer1, Karel Kostev.   

Abstract

BACKGROUND: Large epidemiological databases facilitate the study of medical care in different subgroups of the population and how such care compares with standard treatment guidelines. This study aimed for such analyses regarding utilization of antiepileptic drugs (AEDs) for epilepsy in Germany.
METHOD: The data source was the Disease Analyzer(®) database that is representative for the German population and assembles anonymous demographic and medical (diagnoses, prescriptions) data obtained from the practice computer system of general practitioners and specialists throughout Germany. A total of 43,712 adult patients with an epilepsy diagnosis (International Classification of Diseases, 10th edition [ICD10] code: G40.X) seen in 2010-2012 by 346 neurologists were retrospectively analysed according to sociodemographic characteristics, comorbidity, and AED treatment. Multivariate logistic regression was applied to calculate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs).
RESULTS: As compared with women, men were less likely to receive lamotrigine (OR 0.68; 95 % CI 0.65-0.72; p < 0.001) and were treated preferably with carbamazepine (OR 1.29; 95 % CI 1.23-1.35; p < 0.001). As compared with patients covered by private health insurance (PHI), patients with statutory health insurance (SHI) were treated more often with valproate (OR 1.19; 95 % CI 1.07-1.31; p < 0.001) and showed a higher rate of obesity (SHI: 3.1 %; PHI: 1.6 %; p < 0.001), while PHI was associated with administration of levetiracetam (OR 1.27; 95 % CI 1.16-1.4; p < 0.001). Carbamazepine (OR 1.25; 95 % CI 1.17-1.31; p < 0.001) and primidone (OR 1.23; 95 % CI 1.08-1.38; p < 0.001) were administered to a larger extent in rural versus urban areas. Lamotrigine (OR 1.31; 95 % CI 1.23-1.39; p < 0.001) was used more often in West than in East Germany. Living in an urban community raised the likelihood of being treated with levetiracetam (OR 1.23; 95 % CI 1.17-1.28; p < 0.001).
CONCLUSIONS: In spite of common guidelines, AED treatment differed significantly among adults with epilepsy in Germany. Besides gender, type of health insurance and place of residence strongly influenced AED administration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25005594     DOI: 10.1007/s40263-014-0187-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  16 in total

Review 1.  Global disparities in the epilepsy treatment gap: a systematic review.

Authors:  Ana-Claire Meyer; Tarun Dua; Juliana Ma; Shekhar Saxena; Gretchen Birbeck
Journal:  Bull World Health Organ       Date:  2009-09-25       Impact factor: 9.408

2.  The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one's attitude toward social health insurance.

Authors:  Oliver Schnusenberg; Chung-Ping A Loh; Katrin Nihalani
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

3.  Developing a computer algorithm to identify epilepsy cases in managed care organizations.

Authors:  E Wayne Holden; Elizabeth Grossman; Hoang Thanh Nguyen; Margaret J Gunter; Becky Grebosky; Ann Von Worley; Leila Nelson; Scott Robinson; David J Thurman
Journal:  Dis Manag       Date:  2005-02

4.  Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Authors:  Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Anne Sabers; Emilio Perucca; Frank Vajda
Journal:  Lancet Neurol       Date:  2011-06-05       Impact factor: 44.182

Review 5.  [Morbidity and healthcare differences between insured in the statutory ("GKV") and private health insurance ("PKV") in Germany. Review of empirical studies].

Authors:  J Huber; A Mielck
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-09       Impact factor: 1.513

6.  Sociodemographic disparities in epilepsy care: Results from the Houston/New York City health care use and outcomes study.

Authors:  Charles E Begley; Rituparna Basu; Thomas Reynolds; David R Lairson; Stephanie Dubinsky; Michael Newmark; Forbes Barnwell; Allen Hauser; Dale Hesdorffer; Nora Hernandez; Steven C Karceski; Tina Shih
Journal:  Epilepsia       Date:  2008-11-17       Impact factor: 5.864

7.  Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies.

Authors:  H Becher; K Kostev; D Schröder-Bernhardi
Journal:  Int J Clin Pharmacol Ther       Date:  2009-10       Impact factor: 1.366

Review 8.  Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings.

Authors:  Ana-Claire L Meyer; Tarun Dua; W John Boscardin; José J Escarce; Shekhar Saxena; Gretchen L Birbeck
Journal:  Epilepsia       Date:  2012-10-25       Impact factor: 5.864

9.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

Authors:  Anthony G Marson; Asya M Al-Kharusi; Muna Alwaidh; Richard Appleton; Gus A Baker; David W Chadwick; Celia Cramp; Oliver C Cockerell; Paul N Cooper; Julie Doughty; Barbara Eaton; Carrol Gamble; Peter J Goulding; Stephen J L Howell; Adrian Hughes; Margaret Jackson; Ann Jacoby; Mark Kellett; Geoffrey R Lawson; John Paul Leach; Paola Nicolaides; Richard Roberts; Phil Shackley; Jing Shen; David F Smith; Philip E M Smith; Catrin Tudur Smith; Alessandra Vanoli; Paula R Williamson
Journal:  Lancet       Date:  2007-03-24       Impact factor: 79.321

10.  The role and uptake of private health insurance in different health care systems: are there lessons for developing countries?

Authors:  Isaac Ao Odeyemi; John Nixon
Journal:  Clinicoecon Outcomes Res       Date:  2013-03-05
View more
  5 in total

1.  [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].

Authors:  A Strzelczyk; H M Hamer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

2.  Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy.

Authors:  Samuel Waller Terman; Wesley T Kerr; Carole E Aubert; Chloe E Hill; Zachary A Marcum; James F Burke
Journal:  Neurology       Date:  2021-12-10       Impact factor: 9.910

Review 3.  Valproic Acid in Women and Girls of Childbearing Age.

Authors:  Dorothy Gotlib; Rachel Ramaswamy; Jacob E Kurlander; Alana DeRiggi; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2017-09       Impact factor: 5.285

4.  Audiovisual teleconsultation for patients with epilepsy in primary care in rural Germany: a pilot study on feasibility and acceptance.

Authors:  Gregor Feldmeier; Christin Löffler; Attila Altiner; Anja Wollny; Felix von Podewils; Manuela Ritzke
Journal:  Pilot Feasibility Stud       Date:  2022-09-21

5.  Sociodemographic factors associated with the first administration of anti-seizure medication in patients with focal epilepsy in Western China.

Authors:  Qiong Zhu; Yi Guo; Shuai Ma; Lili Yang; Zhonghua Lin; Hongbin Sun; Guangzong Li; Liang Yu
Journal:  BMC Neurol       Date:  2021-06-29       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.